Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 320-332 , March 2010

Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced-Intensity Conditioning Creates a Platform for Immunotherapy with Donor Lymphocyte Infusion and Recipient Dendritic Cell Vaccination in Multiple Myeloma

  • Henriëtte Levenga

      Affiliations

    • Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • Corresponding Author InformationCorrespondence and reprint requests: Henriëtte Levenga, MD, Department of Hematology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
    • ,
  • Nicolaas Schaap

      Affiliations

    • Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Frans Maas

      Affiliations

    • Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Bennie Esendam

      Affiliations

    • Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Hanny Fredrix

      Affiliations

    • Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Annelies Greupink-Draaisma

      Affiliations

    • Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Theo de Witte

      Affiliations

    • Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Harry Dolstra

      Affiliations

    • Central Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    • ,
  • Reinier Raymakers

      Affiliations

    • Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Received 4 June 2009 ,Accepted 7 October 2009.

References 

  1. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454
  2. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–1120
  3. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480
  4. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591–3593
  5. Levenga H, Levison-Keating S, Schattenberg AV, Dolstra H, Schaap N, Raymakers RA. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant. 2007;40:355–359
  6. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007;110:9–17
  7. Matte CC, Liu JL, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987–992
  8. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415
  9. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100:1903–1909
  10. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124–127
  11. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft versus host disease in human recipients of marrow from hla-matched sibling donors. Transplantation. 1974;18:295–304
  12. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft versus host syndrome in man—a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  14. Lamers KJ, de Jong JG, Jongen PJ, Kock-Jansen MJ, Teunesen MA, Prudon-Rosmulder EM. Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: qualitative and quantitative measurements. J Neuroimmunol. 1995;62:19–25
  15. Willems P, Verhagen O, Segeren C, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood. 2000;96:63–70
  16. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia. 2003;17:630–633
  17. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia. 2003;17:621–629
  18. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single-nucleotide polymorphisms. Leukemia. 2004;18:663
  19. de Vries I, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091–5100
  20. Norde WJ, Overes IM, Maas F, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood. 2009;113:2312–2323
  21. Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet. 2007;3:e103
  22. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009;15:83–91
  23. Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia. 2004;18:659–662
  24. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant. 2006;12:397–407
  25. Figdor CG, de Vries I, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475–480
  26. Lesterhuis WJ, de Vries I, Schuurhuis DH, et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol. 2006;17:974–980
  27. Overes IM, de Rijke B, van Horssen-Zoetbrood A, et al. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol. 2008;141:799–807
  28. Holloway PA, Kaldenhoven N, van Dijk M, et al. Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect. Leukemia. 2004;18:1543–1545
  29. Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma. 2001;42:357–369
  30. Tatsugami K, Eto M, Harano M, et al. Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol. 2004;5:750–752
  31. Kitawaki T, Kadowaki N, Kondo T, et al. Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia. Am J Hematol. 2008;83:315–317
  32. El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93:455–458
  33. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells. Leukemia. 2009;23:605–607

 Financial disclosure: See Acknowledgments on page 332.

PII: S1083-8791(09)00462-5

doi: 10.1016/j.bbmt.2009.10.006

Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 320-332 , March 2010

Article Tools

* Image Usage & Resolution